21st Jun 2018 10:54
LONDON (Alliance News) - Life sciences firm OptiBiotix Health PLC on Thursday said it has signed an exclusive licensing agreement for food supplements containing its products.
The deal has been signed with ALFASIGMA SpA, which will be able to commercialise food supplements containing OptiBiotix's cholesterol and blood pressure-reducing LPLDL product in Italy.
It is for ten years, OptiBiotix said, and an unspecified upfront royalty payment and then annual royalties with a "five figure" guaranteed minimum.
ALFASIGMA is a pharmaceutical company whose core market is Italy. In 2017, OptiBiotix said, it generated revenue of more than EUR1 billion and it operates across the Americas, Europe, Asia, and Africa.
OptiBiotix shares were 1.1% higher Thursday at 63.90 pence each.
Related Shares:
OptiBiotix Health